NGF Gene Therapy Trial Data Published
No benefit detected in double-blind trial with sham surgical controls.
ALL NEWS
5500 RESULTS
Sort By:
- Most Recent
- Most Commented
Results of Ladostigil Trial Published
The Phase 2 study missed its primary endpoint. While fewer developed dementia in the treatment group, the effect was not statistically significant. People on drug had less brain atrophy than those on placebo.
Phase 3 Trial Suggests Pimavanserin Assuages Psychosis in Dementia
The study halted early when the primary endpoint was met, but an unusual trial design and lack of detailed data leave questions unanswered.
Mutant Tau Stiffens Axon Cytoskeleton Near Soma
In neurons derived from FTD patients, morphological changes at the base of the axon render them hyperexcitable.
LRRK Watchers’ Eyes Turn to Inflammation, Autophagy, Kinase
With variants that boost risk for both familial and sporadic Parkinson’s disease, the LRRK2 gene beckons as a prime target for therapy development...
Anti-Agitation Drug Comes Up Short in Phase 3
Negative findings for AVP-786 belie positive findings from a separate Phase 3 trial announced earlier this year.
NIH Funds Translational Research Centers to Accelerate AD Drug Discovery
$73 million to transform big data into open-access targets and drugs for testing in clinical trials.
Could Greasing the Wheels of Lipid Processing Treat Alzheimer’s?
Speakers at AD/PD 2019 reported that AD risk factors mess up lipid metabolism in glial cells. In cellular models, speeding the clearance of fats lessened pathology.
TOM1: A Check on Runaway Inflammation in Alzheimer’s?
The protein helps internalize neuronal interleukin receptors. It also promotes microglial phagocytosis. Does its absence worsen neuroinflammation and Aβ burden?
Tau Natively Unstructured? Not Always, New Study Says
Using chemical cross-linkers to map contacts among amino acids, structural biologists predict that soluble tau is, in fact, a compact globule containing β-sheets poised to snap into a pathological formation.
Pee P75: A Potential Biomarker of ALS Progression?
ALS patients eliminate more p75 neurotrophin receptor than do healthy controls. P75 urine levels rise as disease worsens.
Proteomics Uncovers Potential Markers, Subtypes of Alzheimer’s
Changes in the composition of the cerebrospinal fluid and synapses may reveal novel insights into AD pathology.
New Funding for Tauopathies
A $400,000 prize is to be awarded as part of the new Rainwater program, and $63 million of NIH money will support a research consortium on frontotemporal dementias.
Human Microglia Eat Synapses, More So in Alzheimer’s
Evidence from postmortem human brains and cultured human microglia suggests the immune cells make a meal out of synapses, especially near plaques.
Estrogen’s Benefit Tied to Age: Good for the Young, Bad for the Old
Greater lifetime estrogen exposure protects cognition, while hormone replacement therapy taken at menopause has no cognitive effects at all.
Current Filters
- Date Range : All x